title: Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastases: case report.
abstract: A patient who had a high grade uterine leiomyosarcoma with intraabdominal and pulmonary metastases at the time of diagnosis underwent supracervical hysterectomy, bilateral salpingo-oophorectomy and tumor reductive surgery. Induction chemotherapy achieved a partial response with small amount of residual disease. On achieving a plateau in the response to her induction chemotherapy, she was switched to prolonged oral etoposide at a dose of 50 mg/m2/day 21 days with a 7-day rest period between cycles. Follow up imaging revealed stable disease with a slight decrease in the size of the paraaortic lymphnodes. Prolonged oral etoposide may be considered in patients with advanced high grade leiomyosarcoma of the uterus.
authors.affiliation: Chulalongkorn University Hospital, Bangkok, Thailand.
authors.forename: W
authors.initials: W
authors.lastname: Termrungruanglert
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: S
authors.initials: S
authors.lastname: Piamsomboon
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: C
authors.initials: C
authors.lastname: Tornos
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000284:Administration, Oral; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide